![]() ![]() In this component, the investigators will use previously developed implementation facilitation strategies and resources to train ED providers and staff at approximately 30 diverse EDs in treatment initiation with SL-BUP and XR-BUP and develop ED buprenorphine protocols and procedures. The study will be comprised of four components as outlined below: Condition or diseaseĭrug: CAM2038 Drug: Buprenorphine Sublingual Product Finally, the investigators will (4) develop and validate ED electronic health record (EHR) opioid-related phenotypes, both of which will inform the main RCT. In addition, in an ancillary component of the study, the investigators will (3) assess the use of XR-BUP in ED patients with Clinical Opioid Withdrawal Scale (COWS) scores < 8 in a case series to potentially expand the eligibility of patients in the larger RCT to those presenting with little to no opioid withdrawal symptoms. Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphine (SL-BUP) versus extended-release buprenorphine (XR-BUP) on ED patients' engagement in formal addiction treatment 7-days after their ED visit. ![]() using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. Why Should I Register and Submit Results?.Ultimately, the solution is a collaboration between health care, law enforcement, governmental entities and communities alike, he said. “We established a comprehensive opioid committee to look at how opioids are used in the system and to identify areas where we can have significant impact on the epidemic.” “We have many other efforts, some at a system level and some at the individual hospital level, which are actively pursuing multiple strategies to improve the health of the communities we serve,” Hardesty said. Glenn Hardesty, one of the co-chairs of the system’s opioid steering committee. The initiative is a pilot program for Texas Health Resources, said Dr. “We’ll make you as comfortable as possible.” “If you come in with a badly broken limb, we’re not going to give you a shot of Toradol,” Harris said. The ED is also hydromorphone (or Dilaudid)-free, because the euphoria associated with the drug can trigger addiction in predisposed patients.īut not every kind of pain in every patient can be treated with non-opiates, the doctors agreed. Novocaine nasal spray can help with headaches. Kidney stone pain can be alleviated with intravenous lidocaine. Nguyen said the ED is also using nitrous oxide, or laughing gas, for some types of pain including nerve pain, acute or chronic back pain, suturing and sedation for orthopedic procedures. Some of the analgesics used in the Texas Health Denton ED instead of opioids include Toradol, an intravenous non-steroidal anti-inflammatory, and Ofirmev, which is the IV form of acetaminophen. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |